TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06692491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg,qd Patients with advanced rare tumours who failed to standard treatment carrying EGFR mutations will be administrated with osimertinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib 600mg,bid Patients with advanced rare tumours who failed to standard treatment carrying ALK fusion will be administrated with alectinib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 960mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRAF V600E mutation will be administrated with vemurafenib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Description: Pamiparib 60mg,bid Patients with advanced rare tumours who failed to standard treatment carrying BRCA1/2 mutation will be administrated with pamiparib under the guidance of MTB.
Study: NCT06618638

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Usual care for ADPKD patients
Study: NCT05215873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: a synthetic prostaglandin E1 analogue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: synthetic oxytocin
Study: NCT04943107

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
Study: NCT06580899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular catheter
Description: Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular catheter
Description: Intra-articular catheter pump with existing standard-of-care multimodal pain management protocol in the immediate post-op period

Intervention type: OTHER
Group type: OTHER
Intervention: Routine Standard of Care Treatment
Description: No changes to what would occur outside of the study.
Study: NCT06612853

Intervention type: OTHER
Intervention: Sleep Quality Scale (SQS)
Description: For the pilot testing, each patient will complete the pre-final version of the SQS.~The patients involved in the field study will have to fill in the SQS twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.

Intervention type: OTHER
Intervention: Sleep Quality Scale (SQS)
Description: For the pilot testing, each patient will complete the pre-final version of the SQS.~The patients involved in the field study will have to fill in the SQS twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.

Intervention type: OTHER
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Description: The patients involved in the field test will have to fill in the PSQI twice before treatment, one week apart, to assess reproducibility of the scale and a third time at 3 months after treatment (surgical or conservative) to assess the responsiveness of the scale.
Study: NCT05008055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.
Study: NCT06323044

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Receive MedSupport intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Use MEMS device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Use MEMS device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05204550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: intranasal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: intranasal
Study: NCT06680934

Intervention type: DIAGNOSTIC_TEST
Intervention: Molecular genetic testing and audiometry
Description: Genetic testing and audiometry are the interventions of interest
Study: NCT06674382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical hematopoietic stem cell transplantation
Description: This is a single-arm study in which all patients will undergo haploidentical hematopoietic stem cell transplantation for the treatment of myelofibrosis.~Pre-transplant Evaluation:~Evaluation includes status of primary Disease, donor specific antibodies (DSA), organ function (assessments for heart, liver, lungs, kidneys, and the nervous system), and Spleen size.~Transplantation Protocol:~Conditioning Regimen:~Dac/TT/Bu/Flu/ATG regimen:~Decitabine 100 mg/m², on day -12. Thiotepa (TT) 5 mg/kg/day, on days -11 and -10. Busulfan 0.8 mg/kg body weight, every 6 hours, on days -8 to -6. Fludarabine 30 mg/m², once daily, on days -6 to -2. Anti-thymocyte globulin (ATG) 2.5 mg/kg body weight, once daily, on days -5 to -2.~Transplant Donor: Haploidentical donor. GVHD (Graft-versus-Host Disease) Prophylaxis Regimen: Cyclosporine, mycophenolate mofetil, and short-course methotrexate for GVHD prevention.~Graft:~Target MNC (Mononuclear Cells): 6-8 × 10⁸/kg. Target CD34+ stem cells: 5 × 10⁶/kg
Study: NCT06674109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Description: For the empagliflozin arm, participants will take 10 mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will take a placebo daily.
Study: NCT05502341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/LEN FDC
Description: Tablets administered orally without regard to food

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable Baseline Regimen
Description: SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stable Baseline Regimen
Description: SBR will include a combination of antiretroviral (ARV) regimen. ARV regimen may include the following, except for participants taking a single tablet regimen or taking a complete parenteral regimen (Cabenuva).~* Nucleos(t)ide Reverse Transcriptase Inhibitors:~  * Abacavir~ * Emtricitabine~ * Lamivudine~ * Tenofovir alafenamide~ * Tenofovir disoproxil fumarate~ * Zidovudine~* Non-Nucleosite Reverse Transcriptase Inhibitors:~  * Delavirdine~ * Efavirenz~ * Nevirapine~ * Rilpivirine~ * Doravirine~* Integrase Inhibitors:~  * Bictegravir~ * Cabotegravir~ * Dolutegravir~ * Elvitegravir~ * Raltegravir~* Protease Inhibitors:~  * Atazanavir~ * Darunavir~ * Fosamprenavir~ * Indinavir~ * Lopinavir~ * Nelfinavir~ * Saquinavir~ * Tipranavir~* Chemokine Co-receptor 5 (CCR5) Antagonist:~  * Maraviroc~* Fusion Inhibitors:~  * Enfuvirtide~* gp120 Attachment Inhibitor:~  * Fostemsavir~* Anti-CD4 Monoclonal Antibodies:~  * Ibalizumab-uiyk
Study: NCT05957367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-3116
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral Tablet Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripretinib
Description: Oral Tablet Formulation
Study: NCT06229457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls PLAY program
Description: Girls PLAY program (8-12 weeks) will include 1) a series of in-person sessions, led by Boys and Girls Clubs staff at the Boys and Girls Club sites, and 2) take-home activities. In-person sessions (60-75 min; 2-3x/week) will center around a different developmentally appropriate sport each week. Lesson plans will outline games/activities in which youth engage in fundamental, sport-specific movement skills. Lesson plans will be delivered by Boys and Girls Club leaders using acts of instruction derived from Self-Determination Theory. Take home activities will 1) summarize and add on to the week's in-person sessions and 2) be adapted for delivery by parents and/or self-guided participation by youth. Take-home activities will provide information for engaging in the past week's activities as well as additional activities that parents and youth can participate in together.
Study: NCT06543394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Mailed primer postcard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Mailed primer postcard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Mailed primer postcard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primer postcard
Description: Mailed primer postcard

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: Mailed recruitment letter with usual care message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: Mailed recruitment letter with usual care message framing
Study: NCT04943107

Intervention type: OTHER
Intervention: no intervention
Description: no intervention, only measurement of blood pressure, intraocular pressure, hypertensive history questionnaire, retinal imaging, optical coherence tomography examination etc..
Study: NCT06543394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: Mailed recruitment letter with usual care message framing
Study: NCT06196320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus within 5-10 seconds) within 24 hours ± thrombectomy at treating clinician's discretion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice (which may include intravenous Alteplase)
Description: Intravenous alteplase (0.9mg/kg) within 4.5 hours from stroke onset or standard care (no lysis) ± thrombectomy at treating clinician's discretion
Study: NCT06543394

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control recruitment letter
Description: Mailed recruitment letter with usual care message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter
Description: Mailed recruitment letter with prospect-theory informed message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter
Description: Mailed recruitment letter with prospect-theory informed message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter
Description: Mailed recruitment letter with prospect-theory informed message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral theory-informed recruitment letter
Description: Mailed recruitment letter with prospect-theory informed message framing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 phone calls
Description: Up to 2 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 phone calls
Description: Up to 4 phone call attempts to schedule patient for a clinical pharmacist adherence counseling visit
Study: NCT06337500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neurophysiological measure (EEG)
Description: Cerebral electric activity recorded with EEG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey
Description: Participants complete a survey to evaluate their exposure to screens and their assessment of the laboratory task performed
Study: NCT05887648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SinDance
Description: One face-to-face briefing session (20 min) will be offered to participants in the SinDance group as part of promoting physical activity and safe exercise for older adults.~Participants will be asked to engage in SinDance 3 times a week for 6 weeks. Each session will last for about 30-40 mins, including 5 mins warm up exercise before the game and 5 mins cool down exercise afterwards.~All the game play sessions will be conducted in LB centres. Each participant will play the game individually.~To play the game, participants will dance to the dance moves shown on the screen (on the external monitor or the projected screen) and as they get each move right, they will be awarded points. The more accurate their moves are, the more points they get in the game.~During the gameplay, the participants will be instructed to stop and rest if they are tired. A RN/RA will be on site to observe the safety of exergaming and to help resolve technical issues as they arise.
Study: NCT06199037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1707 placebo
Description: 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection
Study: NCT05651659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIME model in the prevention and treatment of crises in frail community-dwelling people
Description: TIME is a manual-based, multicomponent programme that will include a rigorous assessment of the crises, one or more interdisciplinary case conferences and the testing and evaluation of customised treatment measures.This multicomponent interdisciplinary model consisting of three overlapping phases. First the assessment phase where the care staff and the physician collaborate in a comprehensive bio-psychosocial assessment. The second phase is the reflection phase with interdisciplinary case conferences based on principles from cognitive behavioural therapy and abc-method, where a customized treatment plan is developed. The abc-method from cognitive behavioural therapy is used as an analytic tool for the analyses of the complex challenges in the case conferences. In the third phase the treatment plan is implemented and evaluated systematically.
Study: NCT05591742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FEMIDUR®
Description: Femidur® consist of 2 vaginal lactobacillis; Lactobacillus rhamnosus GR-1® and Lactobacillus reuteri RC-14®. One tablet a day.~Placebo Z Cap V-3 Pla; mainly maltodextrin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Z Cap V-3 Pla
Description: Consist mainly of maltodextrin. One tablet a day.
Study: NCT06438757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JYB1904
Description: Participants will receive JYB1904 every 8 weeks for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Participants will receive Omalizumab every 2/4 weeks for 24 weeks.
Study: NCT06697470

Intervention type: DEVICE
Intervention: Ultrasound and Bioelectrical Impedance Analysis for Muscle Thickness and Fluid Balance Assessment Translation
Description: This intervention involves the use of ultrasound and bioelectrical impedance analysis (BIA) to monitor changes in muscle thickness and assess fluid balance in critically ill patients. Measurements will be taken daily during the patients' ICU stay, with a focus on rectus femoris, tibialis anterior, and biceps brachii muscles, as well as total body fluid compartments. The study aims to explore correlations between muscle thickness variations, fluid balance, and patient outcomes.